Acino
Acino, officially known as Acino Pharma AG, is a prominent player in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 2007, the company has rapidly expanded its operations across Europe, the Middle East, and Africa, establishing a strong presence in these key regions. Acino focuses on developing and manufacturing high-quality generic and specialty pharmaceuticals, with a particular emphasis on innovative drug delivery systems. Their unique approach to formulation and packaging sets them apart in a competitive market. With a commitment to improving patient outcomes, Acino has achieved significant milestones, including numerous product launches and strategic partnerships. The company is recognised for its robust portfolio and dedication to quality, positioning it as a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Acino's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Acino's score of 21 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Acino's reported carbon emissions
In 2023, Acino reported significant carbon emissions, totalling approximately 8,256,500 kg CO2e across Scope 1 and Scope 2. Specifically, emissions from Scope 1 amounted to about 5,047,200 kg CO2e, while Scope 2 emissions were approximately 3,209,000 kg CO2e. In Switzerland (CH), where Acino's headquarters is located, the company recorded Scope 1 emissions of about 2,787,000 kg CO2e, with no reported Scope 2 emissions. Despite these figures, Acino has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction strategies suggests that the company may be in the early stages of developing a comprehensive climate commitment framework. As the pharmaceutical industry increasingly prioritises sustainability, Acino's future climate commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 5,047,200 |
| Scope 2 | 3,209,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Acino is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
